OCD Trial, Recruiting NCT02773082 Sponsor: Northwell Health Condition: OCD
Back to Ocd

OCD Trial, Recruiting

NCT02773082
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with OCD for at least 5 years.
  • Your OCD has been rated as severe or extreme by a medical professional.
  • You have tried at least 3 SSRI medications (a common type of antidepressant used for OCD) and a medication called clomipramine, and they have not helped enough.
  • Your main OCD symptom is not hoarding.
  • You have completed, or genuinely attempted to complete, a type of therapy called Exposure and Response Prevention (ERP).
  • You do not have a serious additional psychiatric condition (such as a personality disorder) or current problems with substance misuse.
  • You meet the medical requirements to have a device called a deep brain stimulator surgically implanted.
  • You are 18 years old or older.
  • You have not previously had surgery to remove or destroy the specific area of the brain that this trial targets.
  • You are not currently pregnant.
  • You do not have any other neurological (brain or nervous system) conditions, including dementia.
  • You do not have a bleeding disorder and are not taking blood-thinning medications.
  • You are able to understand and agree to the trial terms and give your own informed consent.

Who may not be able to join:

  • You are unable to operate the neurostimulator device (the implanted device used in this treatment) by yourself.
  • You are likely to be exposed to a type of heat therapy called diathermy (a treatment sometimes used in physiotherapy — confirm with trial site if you are unsure whether this applies to you).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Albert J Fenoy, MD, Northwell Health

Phone: 7184704152

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Northwell Health
Registry
ClinicalTrials.gov
Start date
6 July 2024
Est. completion
1 January 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Efficacy as indicated by a decrease in obsessive compulsive symptoms as assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov